Navigation Links
Managing Preanalytical Processes for Patient Safety

selecting a device that will capture the patient's demographic information through the armband's barcode. Some important questions to ask are:
  • Does the employee's ID badge have a barcode system to identify the person collecting the blood?
  • Is the patient's armband on an arm or leg that can be used for ID?
  • Does the handheld system use wired or wireless synchronization to communicate between the bedside unit and the server?
  • Is end-user training included in the cost of the equipment on all three shifts, seven days a week?
  • Does the product reduce collection time, and has this been documented?

Use a Unified Procedure that Includes the Specimen:

Paula Santrach, MD, director of phlebotomy at Mayo Clinic, Rochester, MN, notes, "Simplify procedures. Sometimes, ID procedures get complicated, or differ by location or department. We used to have two different procedures, one for blood bank specimens and one for other specimens. It helped us to simplify it into a single procedure. You can harm a patient with a wrong blood draw for a chemistry specimen just as you can for a blood bank specimen." To prevent these issues, a proper system is needed for the blood tube label. Some questions to ask are:

  • Are the labels printed at the bedside?
  • Do they have the proper bar code on them?
  • Is there a mechanism within the system to prevent one patients labels being accidentally placed on another patients tubes?
  • Is there a label design that allows labels to be placed correctly on the tube (vertically down the side as opposed to spiral around the tube or attached like a flag waving in the breeze)?
  • Does the laboratory staff have to re-label the tube when it arrives at the testing area?
  • How much time and tech cost is involved in the re-labeling of the tube?

Educate Staff for Increased Compliance:

Cecelia Wright, MBA, MT (ASCP), gro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Monitoring Patient Glucose Levels: New Advances in software make it easier
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Managing Preanalytical Processes for Patient Safety
(Date:10/2/2008)... - Dr. Robert Weiss, Director of Maryland Lase... to his practice -, BALTIMORE, Oct. 2 /PRNewswire...gist, is among the first physicians in the U.S. to...ermolysis), the latest,state-of-the-art procedure...ationally renowned dermatologist, who is in privat...
(Date:10/2/2008)... GOTEBORG, Sweden, October 2 /- C...ated dose study in xerostomia ("dry mouth"),patien... be studied in 45,dry mouth patients between the a...select a dose for evaluation in a succeeding Phase...ning the cholinesterase inhibitor,physostigmine. I...
(Date:10/2/2008)... QUEBEC CITY, Oct. 2 / ...a global biopharmaceutical company focused on,endo... has entered the,second stage of patient recruitme...ZS-108, a luteinizing hormone-releasing hormone (L...o enter the second stage of patient,recruitment wa...
(Date:10/2/2008)... OXFORD, England, October 2 /- Ci... focused on the fields of allergy and critical,car... clinical study of its,ToleroMune(R) technology in...itive results achieved in an earlier phase II stud...its of the ToleroMune approach to allergy,desensit...
Breaking Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Research uncovers the social dynamics of yellow jackets 2253 1Research uncovers the social dynamics of yellow jackets 2253 2Research uncovers the social dynamics of yellow jackets 2253 3Research uncovers the social dynamics of yellow jackets 2253 4Why recovery from flu may increase odds of bacterial infection 12136 1Old London Launches Skinny Jeans Contest 12131 1Old London Launches Skinny Jeans Contest 12131 2Old London Launches Skinny Jeans Contest 12131 3Old London Launches Skinny Jeans Contest 12131 4Into the abyss 3A Deep sixing carbon 2249 1Into the abyss 3A Deep sixing carbon 2249 2
...NJ – June 4, 2007 – Genta,Incorporated...lts,from a Phase 2 clinical trial of its marketed ...plus rituximab (Rituxan®;,Genentech/IDEC) and ...ory non-Hodgkin’s lymphoma (NHL). The data w...n Society of Clinical,Oncology (ASCO) in Chicago, ...
... WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.,...ators today,reported updated Phase 2 data demonstr...53, tumor responses and increased,survival followi...quamous cell carcinoma of the head and neck. The d...nnual meeting of the American,Society of Clinical ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4
(Date:10/6/2008)... Lutherville-based civil litigation and criminal...on Co. after jury awarded $3.2 million to plaintif...herville, Maryland ((Lexis Nexis) October 6, 2008 ...l.com/ [Miller, Murtha & Psoras] have successf...lf of a Maryland welder who was awarded more than ...
(Date:10/5/2008)...considerable disparities in survival related to ra...ead and neck cancer. Published in the November 15,...f the American Cancer Society, the study indicates...tment could improve outcomes for these cancers amo... studies have examined disparities in cancer survi...
(Date:10/5/2008)...ospitalized kids with painful ailments from broken...killing drugs known as opiates. The medications bl...nstipation, for instance, is one side effect that ...spital stay. , "No parent wants their child in t...Sharek, MD, MPH, medical director for quality mana...
(Date:10/5/2008)...tle exercise goes a long way toward helping severe... and complete important daily tasks, according to ..., In a pre-program assessment where patients repo...per week, individuals who were more active reporte...ed improvements in their ability to perform daily ...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 3Health News:A little exercise goes a long way for severely obese 2
...s from the Harvard School of Public Health now rev...n health risks. They have found that women who car...isk of coronary heart disease. The findings were r... which had collected data on caregiving and corona...
...ming in laboratory studies that one of the substan...hives--may inhibit the development of tooth decay...., found that propolis// considerably reduces denta...r of glucosyltransferase (Gtf) enzymes, enzymes th...
...fferent specialties, recently joined hands to demo...er patients. Dr. Peter Costantino, an otolaryngolo...n fatal tumor in Angela Carrozza’s nasal cavity an...iety of Clinical Oncology, nearly 38,000 cases of ...
...illion people go to the Emergency Room(ER) with ch... Most receive an ECG and other standard tests to d...r serious heart problems. However, ECGs can be com... place. ECGs are also sometimes unable to identify...
Other Medicine News:
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: